Atara Biotherapeutics Inc. (NASDAQ:ATRA) saw an upside of 6.20% to close Tuesday at $17.98 after adding $1.05 on the day. The 5-day average trading volume is 715,760 shares of the company’s common stock. It has gained $18.01 in the past week. An average of 843,005 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 766,654.
ATRA’s 1-month performance is 11.89% or $2.30 on its low of $15.27 reached on 09/13/21. The company’s shares have touched a 52-week low of $11.81 and high of $28.20, with the stock’s rally to the 52-week high happening on 02/08/21. YTD, ATRA has lost -8.41% or -$1.65. However, the current price is down -36.24%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
On Sep 22, 21 days have gone by since the last insider trading activity for Atara Biotherapeutics Inc. (ATRA). Newell Joe (Chief Operations Officer) most recently sold 10,500 shares at $17.00 per share on Sep 22. This transaction cost the insider $178,500. Chief Operations Officer, Newell Joe, sold 3,116 shares at a price of $15.61 on Sep 15. Then, on Aug 30, Chief Operations Officer Newell Joe sold 3,500 shares at a price of $15.00 per share. This transaction amounted to $52,500.
Atara Biotherapeutics Inc. (ATRA) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.19 for the sector.ATRA stock has a beta of 2.15. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 212.82 while the price-to-book (PB) in the most recent quarter is 4.99.
Atara Biotherapeutics Inc.’s quick ratio for the period ended June 29 was 4.40, with the current ratio over the same period at 4.40 meaning that ATRA stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00. The firm’s gross profit as reported stood at $2.45 million against revenue of $309.05 million.
For the quarterly period ending June 29 this year, Atara Biotherapeutics Inc.’s cash and short-term investments amounted to $249.52 million against total debt of $12.18 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected ATRA to announce -$0.89 per share in earnings in its latest quarter, but it posted -$0.91, representing a -2.20% surprise. EBITDA for the quarter stood at more than -$81.19 million. ATRA stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 125.25 million, with total debt at $12.18 million. Shareholders hold equity totaling $84.76 million
Let’s look briefly at Atara Biotherapeutics Inc. (ATRA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 66.49% to suggest the stock is trending Neutral, with historical volatility in this time period at 40.09%.
The stock’s 5-day moving average is $17.40, reflecting a +2.86% or $0.50 change from its current price. ATRA is currently trading +14.81% above its 20-day SMA, +25.30% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +39.16% and -18.94% respectively.
Stochastic %K and %D was 49.01% and 53.04% and the average true range (ATR) pointed at 0.73. The RSI (14) points at 66.27%, while the 14-day stochastic is at 76.28% with the period’s ATR at 0.72. The stock’s 9-day MACD Oscillator is pointing at -0.16 and -0.11 on the 14-day charts.
In the most recent analyst report for Atara Biotherapeutics Inc. (NASDAQ: ATRA), JP Morgan upgraded it to an Overweight rating. They previously had a Neutral rating on the stock. Analysts offering their rating for ATRA stock have a consensus rating for the stock as Buy. Currently, 1 brokerage advisors rate ATRA as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 9 have offered a “buy” rating.
What is ATRA’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $10.00 and a high of $78.00, with their median price target at $27.50. Looking at these predictions, the average price target given by analysts is for Atara Biotherapeutics Inc. (ATRA) stock is $33.00.